New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron ...

Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been awarded a new U.S. patent expanding the coverage of the combination of the company’s proprietary genetic diagnostic to identify patients with specific ...

Adial Pharmaceuticals Inc. ADIL said Wednesday it has completed demonstration batch production for its lead candidate AD04, ...

Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use Disorder (AUD) in heavy drinking patients (defined as less than ten drinks ...

On Wednesday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that the final patient completed the last dose in the pharmacokinetics study of AD04 for Alcohol Use Disorder (AUD) in heavy drinking ...

CHARLOTTESVILLE, VA / ACCESSWIRE / February 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for ...

On Wednesday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark Office. The patent expands the ...

CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...

Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy. Received a positive response from the U.S. Food ...